Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naluzotan - Proximagen

Next Previous
Drug Profile

Naluzotan - Proximagen

Alternative Names: PRX-00023

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EPIX Pharmaceuticals
  • Developer EPIX Pharmaceuticals; National Institute of Neurological Disorders and Stroke; Proximagen
  • Class Antidepressants; Anxiolytics; Piperazines; Small molecules; Sulfonamides
  • Mechanism of Action 5-HT1A serotonin receptor agonists; Sigma-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Epilepsy
  • Discontinued Drug-induced dyskinesia; Generalised anxiety disorder; Major depressive disorder

Most Recent Events

  • 06 Oct 2017 National Institute of Neurological Disorders and Stroke terminates phase II trial in Epilepsy in USA (NCT01281956)
  • 14 Aug 2012 Proximagen has been acquired by Upsher-Smith
  • 05 Mar 2012 Discontinued - Phase-I for Drug-induced dyskinesia in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top